Navigation Links
Joint Venture Formed to Help Health Marketers Navigate Social Media Environment

NEW YORK, Oct. 28 /PRNewswire/ -- Extrovertic and Virilion announced today a joint venture, EV Healthcare, to help healthcare companies engage consumers in an increasingly social communications environment.

(Logo: )

"Innovating to meet the perpetually evolving needs of digital, social and mobile consumers is hard enough," says Dorothy Wetzel, co-founder and executive marketer at Extrovertic. "Doing it in the politically and emotionally charged healthcare arena is the ultimate challenge. But with Virilion's more than a decade of experience dealing with cause-related issues and crisis management, this venture greatly enhances our ability to create new 'pharma-safe' solutions that build brands."

"Virilion has long specialized in digital and social media for categories in the public eye," said Dan Solomon, CEO of Virilion. "We believe this competence, combined with Extrovertic's deep healthcare knowledge and creative acumen, will help pharma clients more effectively engage consumers in today's changing communications environment."

"DTC advertising is under assault. Clients today need new non-traditional creative solutions to help them tell more cohesive and engaging stories across all channels," added Mark Drossman, Extrovertic's co-founder and executive creative director, "and in the process, create more engaged brand advocates."

Extrovertic was founded by industry veterans Dorothy Wetzel -- formerly of Saatchi Healthcare and Pfizer Consumer Marketing -- and Mark Drossman -- formerly of Ogilvy and Euro RSCG -- in January. The agency's client roster includes a number of biotech companies.

Virilion has offices in Austin, Boston, New York and Washington, DC. Since 1997, the firm has worked for clients in categories ranging from food, agriculture and energy to media and entertainment. In the healthcare sector, Virilion has worked for Abbott, the Pharmaceutical Manufacturers of America, and Easter Seals.

EV Healthcare will be led out of the firms' New York offices.

    CONTACT: Mimi Carter, Publicist

SOURCE EV Healthcare

SOURCE EV Healthcare
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
2. Joint Commission Urges Patients to Speak Up About Pain
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Texas Back Institute Leads Way in New Facet Joint Clinical Trial
7. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
8. Orthopaedic Surgeon Shortage Predicted Due to Soaring Joint Replacement Procedures
9. When to Have That Joint Replacement?
10. Beating Blood Clots after Joint Replacement
11. Octogenarians: Not Too Old for Joint Replacement
Post Your Comments:
(Date:11/25/2015)... 2015 Developmental, commercial, and regulatory/legal ... profitability of pharmaceutical products, says GBI Research ... regulatory/legal strategies all play a key role in boosting ... . --> Developmental, commercial, ... in boosting the profitability of pharmaceutical products, says ...
(Date:11/24/2015)... NEW DELHI , November 25, 2015 ... fear invoked due to repeated failure of IVF cycles. ... Rani Bhatia was totally dejected and had lost all hopes that ... the first Indian miracle child conceived after failure of ... to abroad (UK) before they decided to take one last ...
(Date:11/24/2015)... HILL, N.C. , Nov. 24, 2015  In ... research projects in an effort to quickly uncover new ... position. --> --> ... launch a market research project and ensure that all ... company and industry standards. Another major barrier to efficiently ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... , ... In an ongoing Clinical Study conducted by an independent physician, Andrew ... is evaluating the efficacy of its product and its disinfection protocol. This study is ... May 2014 through October 2015 at a 360-bed, acute-care, academic medical center located in ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in ... involving adult stem cell therapies to patients with chronic degenerative medical conditions. Now, ... a Registered Trademark (RTM). , Organizations are required to hold a registered trademark ...
(Date:11/24/2015)... ... November 24, 2015 , ... Dr. Todd S. Afferica, a noted general ... many of his patients. Dr. Afferica now uses the BIOLASE WaterLase iPlus 2.0™ in ... time the doctor uses other traditional cutting tools, such as the scalpel and high-speed ...
(Date:11/24/2015)... ... 2015 , ... In an article published November 12th by Obesity ... are or are not eligible for bariatric surgery. The article explains that candidates for ... than 100 pounds overweight, or have a BMI of 35 and over with at ...
Breaking Medicine News(10 mins):